{{Subject}}
Real Chemistry’s weekly analysis of biopharmaceutical pricing and value news, provided free of charge.
Real Chemistry
Value Report
October 16, 2026
 

Programming Note: Value Report will take a one-week break to rake leaves and tailor our Halloween costumes. We’ll return on October 30 with fresh insights on health policy and prescription drugs. Thank you for being a valued reader.

Medicare Advantage Enrollment Opens Amid Plan Shakeups

The Medicare Annual Enrollment Period opened yesterday, and many seniors may find that their coverage options look very different than a year ago.

After several years of financial pressure, Medicare Advantage plans are reducing benefits, narrowing provider networks, exiting counties and, in some cases, leaving markets altogether. More than 3 million beneficiaries are enrolled in plans that have either been terminated or withdrawn from their county for 2027, meaning they will need to actively select new coverage.

As seniors evaluate their options, the 2027 Medicare Advantage Star Ratings—released by CMS last week—provide another important data point. The ratings help consumers compare plan quality and are tied to measures such as member experience, preventive care and chronic disease management.

This year, fewer plans achieved top ratings after CMS raised performance thresholds and modified its methodology. For example, the share of Medicare Advantage plans with prescription drug coverage earning four stars or higher fell from 44% to 37%, while the number of 5-star contracts declined from 22 to 15.

The results also highlight how much plan quality can vary across the Medicare Advantage landscape. While some insurers, including Humana and Devoted Health, improved their performance, others, such as UnitedHealthcare and Aetna, saw declines in the share of members enrolled in highly rated plans.

At a time when Medicare Advantage continues to face scrutiny over costs and payment policies, the program’s popularity remains difficult to ignore. More than half of eligible Medicare beneficiaries now choose Medicare Advantage coverage, demonstrating the program’s enduring appeal even as plans, regulators and beneficiaries navigate another year of change.

– Megan Hickey, Managing Director

FDA Initiates Reset of Rare Disease Framework

The FDA is laying the groundwork to revamp the regulatory framework for reviewing rare disease treatments in a bid to reduce the “guessing game” of approval decisions.

On Wednesday, the FDA debuted the Rare Disease Framework Initiative to support a “more consistent, predictable and innovative approach” to drug development, according to Acting Commissioner Kyle Diamantas. The initiative outlines a process to identify how the agency can alter procedures and regulations to help developers without changing requirements for safety and effectiveness.

As a first step: the FDA is seeking opinions on how to implement a “fit-for-purpose review” system—one that encompasses everything from pre-clinical trial engagement to post-marketing requirements. The agency also seeks ways to incorporate more engagement with patients and disease experts throughout the review process.

The initiative is viewed as a “reset” of the FDA’s rare disease policy—one that is broader but more measured than the controversial actions of former agency leaders Marty Makary and Vinay Prasad. Both officials spearheaded a proposed “plausible mechanism” pathway for rare disease approvals, which Acting Commissioner Diamantas later clarified is not official agency policy.

The FDA promises ample chances for patient communities and other stakeholders to offer feedback on the initiative, starting with a public meeting scheduled for Wednesday, October 28.

– Andrew Wishon, Editor-in-Chief

Circled on Our Calendar
Quotes of the Week
  • “If the [Vaccine Injury Compensation Program] is rendered a shell of itself by federal policy, private vaccine makers could retreat from the U.S. market, viewing it as too risky with too much legal exposure to do business. That could lead to vaccine shortages — and a situation where Americans who want vaccines can no longer get them…” – Joel Dodge, STAT
  • “MFN agreements are largely tied to the current administration…manufacturing plants are multi-year commitments that will outlast the political cycle. The most enduring legacy may therefore be where medicines are developed and made, rather than the MFN prices negotiated today” – Jaehyuk Lee et al., pharmaphorum
  • “Watching the Dodgers defeat the Atlanta Braves in the Major League Baseball playoffs…I was struck again by the similarities between the L.A. franchise and the pharma that always seems to come out ahead: Eli Lilly” – Heather McKenzie, BioSpace
  • “The generic industry isn’t seeking special treatment. It just makes sense to support the one part of American healthcare that reliably reduces the cost of medicine, so we can keep doing it” – John Murphy III, DC Journal
Other News
See you in two weeks …
–  Real Chemistry
 
Know a friend or colleague that would enjoy the Value Report?
Invite them to sign up here.
© Real Chemistry, All Rights Reserved.